Reports

To help health care providers, policy decision-makers, and consumers make well-informed decisions about the optimal use of solvent/detergent-treated human plasma (S/D plasma), the Canadian Agency for Drugs and Technologies in Health's (CADTH) completed research and resulting recommendation are now available.

Summary Reports:

• Project in Brief — a one-page summary of the research and key messages

Final Reports:

• Optimal Therapy Recommendation for the Use of Solvent/Detergent-Treated Human Plasma

• A Systematic Review of Clinical, Laboratory and Safety Outcomes Associated with Use of Octaplas in Multiple Clinical Indications (commissioned in 2007 by and posted with permission from Canadian Blood Services)

• Addendum to A Systematic Review of Clinical, Laboratory and Safety Outcomes Associated with Use of Octaplas in Multiple Clinical Indications

• Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis

• Ethical Assessment: Open versus Restricted Access and Optimal Use of Solvent/Detergent-Treated Human Plasma (Octaplas)

The addendum listed above summarizes updated information released since the systematic review was originally commissioned by Canadian Blood Services in 2007.

CADTH originally published Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis in March 2008. A new report was published in March 2011 (listed above), which includes more recent estimates of the risks of transfusion-related adverse events and updated cost-effectiveness findings.